These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

860 related items for PubMed ID: 11230751

  • 1. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR.
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R, Ghisetti V, Pittaluga F, Marchiaro G, Rocca G, Borghesio E, Rizzetto M, Saracco G.
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [Abstract] [Full Text] [Related]

  • 4. Ribavirin in the treatment of hepatitis C.
    Abonyi ME, Lakatos PL.
    Anticancer Res; 2005 Aug; 25(2B):1315-20. PubMed ID: 15865084
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Non-interferon-based therapy: an option for amelioration of necro-inflammation in hepatitis C patients who cannot afford interferon therapy.
    El-Zayadi AR, Attia M, Badran HM, El-Tawil A, Zalata K, Barakat E, Selim O, El-Nakeeb A, Saied A.
    Liver Int; 2005 Aug; 25(4):746-51. PubMed ID: 15998425
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
    Yu ML, Chuang WL, Dai CY, Lee LP, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Tsai SL, Kuo HT.
    Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
    [Abstract] [Full Text] [Related]

  • 12. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC.
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL, Guindi M, Tomlinson G, Heathcote J.
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.